Patients with decompensated cirrhosis, particularly those with acute‐on‐chronic liver failure (ACLF), show profound alterations in plasma metabolomics. The aim of this study was to investigate the effect of treatment with simvastatin and rifaximin on plasma metabolites of patients with decompensated cirrhosis, specifically on compounds characteristic of the ACLF plasma metabolomic profile. Two cohorts of patients were investigated. The first was a descriptive cohort of patients with decompensated cirrhosis (n = 42), with and without ACLF. The second was an intervention cohort from the LIVERHOPE‐SAFETY randomized, double‐blind, placebo‐controlled trial treated with simvastatin 20 mg/day plus rifaximin 1,200 mg/day (n = 12) or matching placebo (n = 13) for 3 months. Plasma samples were analyzed using ultrahigh performance liquid chromatography–tandem mass spectroscopy for plasma metabolomics characterization. ACLF was characterized by intense proteolysis and lipid alterations, specifically in pathways associated with inflammation and mitochondrial dysfunction, such as the tryptophan–kynurenine and carnitine beta‐oxidation pathways. An ACLF‐specific signature was identified. Treatment with simvastatin and rifaximin was associated with changes in 161 of 985 metabolites in comparison to treatment with placebo. A remarkable reduction in levels of metabolites from the tryptophan–kynurenine and carnitine pathways was found. Notably, 18 of the 32 metabolites of the ACLF signature were affected by the treatment. Conclusion: Treatment with simvastatin and rifaximin modulates some of the pathways that appear to be key in ACLF development. This study unveils some of the mechanisms involved in the effects of treatment with simvastatin and rifaximin in decompensated cirrhosis and sets the stage for the use of metabolomics to investigate new targeted therapies in cirrhosis to prevent ACLF development.
Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19
The COVID‐19 pandemic highlighted the challenges delivering face‐to‐face patient care across healthcare systems. In particular the COVID‐19 pandemic challenged the imaging community to provide timely access to essential diagnostic imaging modalities while ensuring appropriate safeguards were in place for both patients and personnel. With increasing vaccine availability and greater prevalence of vaccination in communities worldwide we are finally emerging on the other side of the COVID‐19 pandemic. As we learned from our institutional and healthcare system responses to the pandemic, maintaining timely access to MR imaging is essential. Radiologists and other imaging providers partnered with their referring providers to ensure that timely access to advanced MR imaging was maintained. On behalf of the International Magnetic Resonance in Medicine (ISMRM) Safety Committee, this white paper is intended to serve as a guide for radiology departments, imaging centers, and other imaging specialists who perform MR imaging to refer to as we prepare for the next pandemic. Lessons learned including strategies to triage and prioritize MR imaging research during a pandemic are discussed.Level of Evidence5Technical EfficacyStage 5
Abdominal Wall Vascularized Composite Allotransplantation: A Scoping Review
AbstractBackground Abdominal wall vascularized composite allotransplantation (AW-VCA) is a novel reconstructive technique used for large abdominal wall defects in combination with intestinal transplantation (ITx) or multivisceral abdominal transplantation (MVTx). Since the introduction of this procedure, several studies have been published reporting their experience. This study aims to present a scoping review looking at all available evidence-based medicine information to understand the most current surgical techniques and clinical outcomes.Methods This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) extension for scoping reviews checklist. A comprehensive research strategy of several databases was conducted.Results A total of 31 studies were included in this review, which comprised animal, cadaveric, and human studies. In human studies, four surgical techniques with high flap survival rates and low complication rates were found. In cadaveric studies, it was shown that the use of iliofemoral cuff-based flaps provided adequate tissue perfusion to the abdominal wall graft. Also, the use of thoracolumbar nerves have been described to provide functionality to the AW-VCA and prevent long-term muscle atrophy.Conclusion AW-VCA is a safe and efficient alternative for patients with large and complex abdominal wall defects. The future holds a promising evolution of a functional AW-VCA, though surgeons must face and overcome the challenge of distorted anatomy frequently present in this population. Forthcoming studies with a better level of evidence are required to evaluate functionality and differences between surgical techniques.
Osteoid osteoma is a small, benign tumor usually of endochondral bone, affecting mainly the long bones of the extremities and occurring not uncommonly among children. It produces pain which may disturb sleep and interfere with normal activities. The roentgenogram reveals a radiolucent area surrounded by osteosclerosis. This is suggestive of osteoid osteoma but differential diagnosis from certain other neoplastic, inflammatory and metabolic lesions of bone must be made. Thirteen children with osteoid osteoma have been treated by excision of the lesion at the Mayo Clinic. The results have been uniform alleviation of symptoms. This experience and that obtained elsewhere has shown that incomplete removal of the nidus may lead to recurrence of the symptoms.
CONGENITAL CORRECTED TRANSPOSITION OF THE GREAT VESSELS: A STUDY OF 33 CASES
Thirty-three cases of corrected transposition of the great vessels are analyzed: 31 of corrected transposition in situs solitus, and two of corrected transposition in situs inversus. In 18 of these 33 cases, of which 64% were males, diagnosis was confirmed by necropsy or operation. There was no history of congenital heart disease in the families of any of these patients. The person whose sole anomaly is corrected transposition has no hemodynamic basis for symptoms. Symptoms are the result of associated lesions, the most common of which are anomalies of the left atrioventricular valve usually causing incompetence, ventricular septal defects, pulmonary valvular stenosis, and advanced disturbances of atrioventricular conduction. Physical findings in corrected transposition depend upon these associated defects. Noncardiac associated anomalies are rare. Anteroposterior thoracic roentgenograms may suggest the diagnosis, particularly when a narrow waist is present at the base of the heart, accompanied by the absence of a pulmonary-artery "knob" and the presence of an enlarged left atrium. Electrocardiographic features that should suggest corrected transposition are atrioventricular block (particularly 2:1 or complete heart block), abnormal P waves, absent or low R voltage in aVR, an initial Q wave in leads 3, aVR, aVF and V1, absence of a Q wave in lead V6, upright T waves across the precordium in children, and a clockwise spatial loop in the frontal plane. Cardiac catheterization may be diagnostic in this malformation when careful documentation is made of the location of the atrioventricular valves and their relation to the semilunar valves, together with the position of the great vessels in the anteroposterior and lateral views. Alteration of hemodynamics is secondary to associated malformations. Inability to enter the pulmonary artery during catheterization should arouse suspicion, and in these cases, particularly, angiocardiography can be diagnostic. The decision as to whether the most frequently associated malformations exist as isolated entities, or whether they are present in combination with corrected transposition, appears to be the main differential problem–together with the differentiation of corrected transposition with associated cyanosis from complete (that is, uncorrected) transposition. Surgical treatment of corrected transposition has been difficult because of complete atrioventricular block before or after operation, residual incompetence when deformed left atrioventricular valves were present, and the mirror-image arrangement for the coronary arteries. The most common cause of death was cardiac failure, often with a terminal bout of pulmonary edema. The average age at death in this series was about 14 years, with a median age at death of about 4 years. A review of the literature again emphasizes the association of corrected transposition with some degree of atrioventricular block evidenced on the electrocardiogram. The most frequently reported associated cardiac lesions were ventricular septal defect, pulmonary stenosis or atresia, patent ductus arteriosus, and dextrocardia. The incidence of anomalies of the left atrioventricular valve in these reported cases has probably been underestimated.
Reply: Regret after Gender-affirmation Surgery: A Systematic Review and Meta-analysis of Prevalence
Abstract Background Nontuberculous mycobacteria (NTM) are resistant to numerous antibiotics and lead to significant morbidity and mortality. Omadacycline (OMC) is an aminomethylcycline antibiotic that is Food and Drug Administration-approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. Furthermore, OMC has shown in vitro activity against NTM. Given that real-world evidence is lacking, our primary objective was to evaluate the clinical success and tolerability of OMC when used for a variety of NTM infections. Methods This was a multicenter, retrospective, observational study conducted from January 2020 to June 2021. We included all patients ≥ 18 years of age that received OMC of any indication for Mycobacterium spp. The primary outcome was clinical success, defined as a lack of all-cause mortality, lack of persistence or re-emergence of infection during or after therapy, and lack of alteration of OMC. Incidence of adverse effects potentially attributable to OMC and reasons for OMC utilization were also analyzed. Results A total of 31 patients were included from 12 geographically distinct academic health systems (median age: 57 (IQR, 45-63) years; 45% male; 81% Caucasian). The majority of isolated pathogens were Mycobacterium abscessus complex (84%) and of those with subspeciation performed (54%), the majority (86%) were subsp. abscessus. The primary infections were of pulmonary origin (67%) and the median (IQR) duration of OMC therapy was 5.3 (3.2-9.4) months. Most isolates did not have OMC susceptibility conducted (87%), while the majority did for tigecycline (90%). Clinical success was reported in 81% of the population. Most patients were on combination antimicrobial therapy, and 39% of patients reported an adverse effect while on OMC (58% gastrointestinal distress). The majority of patients were prescribed OMC due to ease of administration (61%) and antimicrobial resistance to previous antibiotics (42%). Conclusion OMC may be a potential option for the therapy of NTM infections. Prospective, randomized clinical trials are needed to confirm our preliminary findings. Disclosures Julie V. Philley, MD, Paratek Pharmaceuticals (Advisor or Review Panel member)Paratek Pharmaceuticals, Inc. (Consultant) Michael P. Veve, Pharm.D., Cumberland (Grant/Research Support)Paratek Pharmaceuticals (Research Grant or Support) Michael J. Rybak, PharmD, MPH, PhD, Paratek Pharmaceuticals (Research Grant or Support)